• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Canopy Growth Corporation

    6/17/26 7:50:48 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    S-8 1 tm2617986d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 17, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

    FORM S-8

     

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

     

    CANOPY GROWTH CORPORATION 

    (Exact Name of Registrant as Specified in Its Charter)

     

    Canada   N/A
    (State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification No.)

     

    1 Hershey Drive 

    Smiths Falls, Ontario, Canada K7A 0A8
    (Address of Principal Executive Offices)
    (Zip Code)

     

    Canopy Growth Corporation Omnibus Equity Incentive Plan
    (Full Title of the Plan)

     

    CT Corporation System 

    1015 15th Street N.W., Suite 1000 

    Washington, DC 20005 

    (Name and Address of Agent for Service)

     

    (202) 572-3100
    (Telephone Number, Including Area Code, of Agent for Service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer x
    Non-accelerated filer ¨ Smaller reporting company ¨
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Canopy Growth Corporation (the “Registrant” or the “Company”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register 47,384,690 additional common shares (“Common Shares”) of the Registrant reserved for issuance under the Registrant’s Omnibus Equity Incentive Plan (the “Plan”) resulting from the “evergreen” nature of the Plan, which provides that Common Shares covered by awards which have been settled, exercised or terminated shall be available for subsequent grants under the Plan and the number of awards available to grant increases as the number of issued and outstanding Common Shares increases. This Registration Statement hereby incorporates by reference the contents of the Registrant’s previous Registration Statement on Form S-8 filed with the SEC on October 25, 2023 (File No. 333-275167).

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    In accordance with the instructional Note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of Form S-8 has been omitted from this Registration Statement on Form S-8 for offers of the Registrant’s Common Shares pursuant to the Plan. The documents containing the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428(b)(1) under the Securities Act of 1933, as amended.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated herein by reference:

     

    ·Our Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on June  15, 2026;

     

    ·Our Current Reports on Form 8-K filed with the SEC on May 15, 2026 (excluding information furnished under Item 7.01) and May 27, 2026; and

     

    ·The description of the Common Shares included as Exhibit 4.1 to our Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on June 15, 2026.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement:

     

    Number   Description
    4.1   Certificate of Incorporation and Articles of Amendment of Canopy Growth Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the SEC on June 1, 2020).
    4.2   By-Law No. 1 of Canopy Growth Corporation (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the SEC on November 8, 2021).
    4.3   Amendment to Articles of Canopy Growth Corporation, filed on December 15, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 18, 2023).
    4.4   Articles of Amendment to Articles of Incorporation of Canopy Growth Corporation, filed on April 12, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 16, 2024).
    4.5   By-Law No. 2 of Canopy Growth Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 27, 2026).
    5.1*   Opinion of Cassels Brock & Blackwell LLP.
    23.1*   Consent of PKF O’Connor Davies, LLP.
    23.2*   Consent of Cassels Brock & Blackwell LLP (included in Exhibit 5.1 above).
    24.1*   Powers of Attorney (included on the signature page to this Registration Statement).
    99.1#   Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the SEC on November 9, 2023.
    107*   Filing Fee Table

     

    * Filed herewith. 

    # This document has been identified as a management contract or compensatory plan or arrangement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Toronto, Province of Ontario, Canada, on this 17th day of June, 2026.

     

    CANOPY GROWTH CORPORATION  
       
    By: /s/ Luc Mongeau  
      Name: Luc Mongeau  
      Chief Executive Officer  

     

    POWERS OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Luc Mongeau and Thomas Stewart, and each of them, any of whom may act without the joinder of the other, the true and lawful attorney-in-fact and agent of the undersigned, with full power of substitution and resubstitution, for and in the name, place and stead of the undersigned, in any and all capacities, to sign any and all amendments, including any post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    This Power of Attorney may be executed in multiple counterparts, each of which shall be deemed an original, but which taken together shall constitute one instrument.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name   Title   Date
             
    /s/ Luc Mongeau   Chief Executive Officer and Director   June 17, 2026
    Luc Mongeau   (Principal Executive Officer)    
             
    /s/ Thomas Stewart   Chief Financial Officer   June 17, 2026
    Thomas Stewart    (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ David Lazzarato   Director, Chair of the Board   June 17, 2026
    David Lazzarato        
             
    /s/ Theresa Yanofsky   Director   June 17, 2026
    Theresa Yanofsky        
             
    /s/ Margaret Shan Atkins   Director   June 17, 2026
    Margaret Shan Atkins        
             
    /s/ Joseph Bayern   Director   June 17, 2026
    Joseph Bayern        
             

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, as amended, the Authorized Representative has duly caused this Registration Statement to be signed on its behalf by the undersigned, solely in his capacity as the duly authorized representative of Canopy Growth Corporation in the United States, on this 17th day of June, 2026.

     

    By: /s/ Thomas Stewart  
      Name: Thomas Stewart  
      Title: Chief Financial Officer
    Canopy Growth Corporation — Authorized Representative in the United States
     

     

     

     

    Get the next $CGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    3/27/2026Buy
    Canaccord Genuity
    11/10/2025Sell → Hold
    The Benchmark Company
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    More analyst ratings

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Atkins M Shan was granted 108,324 shares, increasing direct ownership by 262% to 149,714 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    6/22/26 4:39:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Lazzarato David Angelo was granted 162,485 shares, increasing direct ownership by 226% to 234,533 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    6/22/26 4:38:23 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bayern Joseph was granted 108,324 shares, increasing direct ownership by 271% to 148,324 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    6/22/26 4:36:44 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis

    Full-year 2026 growth driven by net revenue increases of 20% in Canada adult-use cannabis and 18% in Canada medical Completed acquisition of MTL Cannabis, positioning Canopy Growth as Canada's leading medical cannabis company by revenue Ended the fiscal year with $131.3M of net cash following strategic recapitalization completed in January 2026 Strategic decisions and financial discipline in FY2026 establish a foundation for acceleration and growth Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the three months ended March 31, 2026 ("Q4 FY2026") and the fiscal year ended March 31, 2026 ("FY2026"). All fi

    6/15/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Claybourne's Frosted Flyers Wins 'Best Infused Pre-Roll' at 2026 Grow Up Awards

    Claybourne extends its market share momentum with expanded Frosted Flyers lineup One of Canada's fastest-growing cannabis brands adds new variety formats built for flavour, discovery and summer pre-roll season Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced that Claybourne's Frosted Flyers Variety Pack has been awarded Best Infused Pre-Roll at the 2026 Grow Up Awards, presented during the annual Grow Up Conference & Expo in Toronto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608930080/en/Frosted Flyers Variety Pack Building on that recognition, the Company also anno

    6/8/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition

    Pablo's Revenge, Dante'z Inferno, and Frost'd Flakes launched under Tweed brand Up to five additional strains expected to follow in June 2026 Company targeting rapid growth in Germany's medical cannabis market Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. ("MTL"), a wholly-owned subsidiary of the Company. The dual milestone represents the Company's first international product release following its recent acquisition of MTL. This press release features multimedia. View the full release

    5/29/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    SEC Filings

    View All

    SEC Form S-8 filed by Canopy Growth Corporation

    S-8 - Canopy Growth Corp (0001737927) (Filer)

    6/17/26 7:50:48 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    6/15/26 7:06:39 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Canopy Growth Corporation

    10-K - Canopy Growth Corp (0001737927) (Filer)

    6/15/26 6:46:54 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis

    Full-year 2026 growth driven by net revenue increases of 20% in Canada adult-use cannabis and 18% in Canada medical Completed acquisition of MTL Cannabis, positioning Canopy Growth as Canada's leading medical cannabis company by revenue Ended the fiscal year with $131.3M of net cash following strategic recapitalization completed in January 2026 Strategic decisions and financial discipline in FY2026 establish a foundation for acceleration and growth Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the three months ended March 31, 2026 ("Q4 FY2026") and the fiscal year ended March 31, 2026 ("FY2026"). All fi

    6/15/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

    Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth $298MM cash and cash equivalents, which exceeds debt balances by $70MM at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern have been resolved Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). Al

    11/7/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign

    New window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro

    4/23/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care